Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whatever. Still no real hard answers from you or the company.
Surprisingly the stock is trading at a market cap indicating approval. Over a $400 million market cap pre approval has been a good indicator since the 90s.
Say what! At least make a coherent argument. If you can answer some of my questions then I will yield and say you are the better investor.
For real. I am a tired of the same old performance long time investor here. May 10 may have had loads of illegal spoofing but prior to then this company couldn’t and still cannot meet any scheduled goals. This company could use a Dr. Duffy in charge right now.
Right. Like many others I own long shares and have been invested for over a decade. The management has mad some pretty bad decisions but always have protected their own bacon. No transparency. It is always hide and seek.
If you think they are being up front. How many specials were manufactured last year? What is the $ amount brought in? What are we paying Advent and what are we paying for our obligations on the facility? What is a range of revenue expected if approved? I could go on but that is what Q&A is for.
It is easy to hang on because you expect timely execution based on implied goals. Here is one. It has been about 1.5 years since the last ASM. At the last ASM they implied filing with 4 RAs. No one could possibly expect that after a year and a half they only filed with the one. The goals put forward at an annual meeting just drag on and with no explanation because there are no quarterly calls with Q&A to ask them how soon before they get their feet out of cement. So an investor waits and hates.
What happened the last time questions from this board were submitted? I will tell you. She ignored all of them and answered the one question she wanted to answer. The answer was not very satisfactory because it really didn’t answer when TLD was coming. She just stated TLD was their 1st, 2nd and 3rd priority.
Without Q&A with accredited analysts you might as well ask if why is there air.
I would doubt the Judge is viewing the case based on the vote. It has to do with the rights of weaker minority shareholders. The plaintiff has less shares than most of us here and yet the case continues.
And the plaintiff is saying management cannot allow shareholders to be devalued and then make themselves whole.
Thanks for the input. Tough to put together the reasons without some posters. Management’s lack of input has me relying on input from posters. It appears we have some tech Kalinski needs and NWBO gets trials run in other indications along with the Kalinski tech.
After digesting this in-license, it sounds pretty good. It will still take a year or three to see if my take is correct. But, sounds like a good deal.
Well they get very handsome salaries. It is not free.
Sure they deserve a performance bonus. Notice the word “performance”. It is supposed to be based on performance. The reward comes during the year the performance occurs like every public company. Then you experience the fate of value to shares that every shareholder experiences.
Especially the shipping container. The one time consuming issue is the lysate and how that is done in coordination with the tumor sample. I have read the machines are expensive.
They already have set it up.
1. User ships sample in FedEx
2. Advent intake, process
3. Advent ships via FedEx to user
4. User (oncologist) administer
The shipping containment system has been designed for this. All processing from intake to shipping out has been computerized. It was a big deal when they hired the workflow software firm. I haven’t kept track but there are probably more than 100 employees now at Sawston. I imagine a supplier like Walgreens will distribute the initial packaging for sample shipment. Even if a BP purchased the company they would be using the Sawston facility. All the work has been done and tested. Especially the packaging.
Nice work. At the moment the most important aspect of the licensing is more visibility with the investment community. Something that has been lacking in the past.
It is just that shareholders should know the breakdown. What each phase of building has cost and what is the deal when commercial production begins.
It is that simple. Otherwise it feels like hide and seek.
Agree on it all. Well stated. Why I voted “NO” on bonuses. Without transparency and accountability tough to see their point of view. It was tough for me always. Award yourself bonuses for each year for what you accomplished like a normal company. Not one lump sum after all shareholders have suffered through devaluation.
You didn’t have all the information. A shareholder didn’t even comprehend they would take years following DL to provide TLD. The schedule didn’t come close to what was implied. There was a great lack of information regarding timelines for operations. Lack of proper and open Q&A and lack of quarterly updates kept shareholders very much lacking information. We didn’t even know we were paying for technology with Kalinski last year.
Doc - Well written and easy to understand. I thank you for the response.
What is missing is how this dendritic cell technology is different from the capability we already have. Also what are the synergies that make this a good fit. Are the partners looking for manufacturing with Eden set up at their facility? Other than Kalinski running trials what is the final endgame. Why would Kalinski want to team exclusively? What are we offering them other than money that a larger BP could offer them?
This agreement is far from fluff. It is worth beaucoup $ once the indications hit. They can be accessed of lack of transparency when they did not provide this prior alliance a year ago.
I agree. I hold my shares and think the technology is a winner. The patents are worth multiples of this market cap but I think the Plaintiff will win because it is a valid argument. If a bonus is deserved for 2023 then give them a bonus. Each year in service they should be rewarded for the accomplishments of that year. A 20% true up following massive dilution of shareholders is pretty egregious.
Corrected myself quite a while ago. But thanks.
I am a no based on transparency and accountability on a true up. As far as the recent news it is typical we need to spend collective time trying to figure out what they are stating.
Right. I reread the second to last paragraph.
So looks pretty good. They do all the trials and if approved we sell the product and pay them 4%. Not bad if I read it correctly.
Thanks. Looks like colorectal and ovarian cancer.
If they sell product NWBO gets 4% of sales. Like a licensing fee. It would be nice to know what 3 cancer indications they are going after in the phase II trials.
I am sure they have the votes so how you voted probably has no meaning. They called you because they need a certain amount of shareholders voting.
Her salary. When she starts meeting implied timelines, goals and moves the share price in a positive direction she would be entitled to a bonus. Also, the thought she is personally writing patents is ridiculous. They have consultants for everything.
I believe there was spoofing. And I believe naked shorting happened years ago. I do not believe the naked shorting now. Our dilemma is from the type of constant finance conundrum made possible by management combined with the illegal spoofing a couple of years ago.
As far as LP and Les they do not give me confidence. I welcome a change that I have called for years ago. Even with approval which I expect to come. Tired of being lied to by omission.
If. I doubt it. But if you say so I will not argue the point. For many long years the talk of this board is LP will trap all the naked shorts. If she stepped down today she just might trap them.
3 years? More like a decade.
I disagree. A hostile takeover still has a poison pill. Shares you own will be upped to make it painful to the buyer. Giving an extremely large gift to the top two players makes it easier for them to take the entity private. That would be another lawsuit in the making. Also a large amount of shares to LG and LP lowers any eps when profits come along. That will lower your share price.
I am for bonuses but not this kind. If they get the votes or not, the judge probably will side with the plaintiff.
Interesting idea.
My guess is the new Director. Better than a deal with Streeterville. That is the vulture financing we got for years. A refreshing change. The only good thing I can say about management lately.
SOC is paid for by insurance. The patient’s and their families are reticent as well as the physicians. Right to try means the patient’s insurance will not pay. Faced with that situation how many families would put the money up? A combo trial is a different story. You would end up getting the vaccine with all expenses paid.
An accredited investor is retail. Not a fund or institution. Many here who bought in the open market can file they have the net worth.
In the same boat.
Recent retail sales are “C” share buyers. Plenty on this board have bought “C” shares. At higher prices than 46 cents. I do not mind giving them a vote for a bonus but let them execute, provide accountability and transparency. I have not seen much or any of this for many years. Going back to the rift with Woodford and the hold on screening. That is a decade long.
Advent isn’t the jewel. NWBO owns the patents for the process and owns Flaskworks. As a part of lacking transparency, shareholders do not know what % Advent will make during commercial production. Just one of the many areas this management team fails inform.
I am a believer in the technology and happy to see it is finally coming to fruition. But, I have voted against outrageous bonuses without transparency and accountability. The lawsuit has merit. Management doesn’t have the right to say we deserve 20% of the company. Each year they were entitled to a certain bonus based on performance. I cannot say their execution has been well thought out over the years. So, again I am a “NO” even if it is an exercise in futility.
I am a bit more sanguine about the sale of common. It could have easily been a loan. It brings some analysis and possible investment recognition.
I wonder how much the new director had in this decision because it is a better direction than the Big Boob Show.